A Quality Improvement Initiative to Decrease Time to Analgesia in Patients With Sickle Cell and Vaso-Occlusive Crisis: A Population With Disparities in Treatment

Tyler Arnold 1,2, R. Lane Coffee Jr. 1, Leon Rosenberg 1,2, Seethal A. Jacob 1,2, Sean Thompson 1,2, Heather Saavedra 1,2, Stephen John Cico 1,2, Brian Wagers 1,2

1. Emergency Medicine, Indiana University School of Medicine, Indianapolis, USA
2. Pediatrics, Indiana University School of Medicine, Indianapolis, USA
3. Internal Medicine, University of Central Florida College of Medicine, Orlando, USA
4. Clinical Sciences, University of Central Florida College of Medicine, Orlando, USA
5. Office of Graduate Medical Education, University of Central Florida/Hospital Corporation of America (HCA) Florida Healthcare Graduate Medical Education (GME) Consortium, Orlando, USA

Keywords: disposition, analgesia, plan-do-study-act, quality improvement, sickle cell disease, vaso-occlusive crises

Abstract

Introduction: Vaso-occlusive crises (VOCs) are the leading cause of emergency department (ED) visits and hospitalizations in patients with sickle cell disease (SCD). Timely administration of analgesia, within 60 minutes of patient registration, is the standard of care for SCD patients with VOCs. Patients with VOCs have longer times to initial analgesia compared to similar painful conditions. The primary aim of the project is to have 75% of patients with VOCs receive initial analgesia within 60 minutes of being registered, the current recommended time frame from the National Heart, Lung, and Blood Institute (NHLBI).

Methods: A multi-disciplinary team used quality improvement (QI) methodology to develop a plan involving multiple Plan-Do-Study-Act (PDSA) cycles. A rapid evaluation process was employed which included notification of a patient with a VOC being placed in a room, rapid evaluation by all team members and use of an electronic order set.

Results: The aim was met 72% of the time during our intervention period, compared to 17% pre-intervention. Average time to initial analgesia was decreased from 61 minutes to 42 minutes (p-value < 0.001), while time to disposition was also decreased when time goals were achieved.

Conclusion: Using a rapid evaluation process we were able to decrease time to initial analgesia in a patient population that has previously experienced delays in care and decrease overall time to disposition.

Introduction

Sickle cell disease (SCD) is the most common inherited hematologic disorder in the United States, affecting over 100,000 Americans [4], with the African American population most affected [2]. A mutation in the β-globin gene leads to an abnormal hemoglobin variant causing sickling of red blood cells. This sickling leads to vaso-occlusion in the blood vessels, leading to complications such as severe pain. These painful episodes, known as vaso-occlusive crises (VOCs), begin as early as six months of age [3]. Roughly one-third of children with SCD experience a VOC by the age of one and almost all patients with SCD will experience a VOC by the age of four [3]. Pain is the leading cause of emergency department (ED) visits in patients with SCD [4].

A study has shown that SCD patients wait longer to be seen by a physician, as well as for initial analgesia, compared to similar painful conditions [5]. In addition, African American patients have delayed delivery of analgesia compared to the general population [5,6]. Delayed or inadequate treatment of VOCs can be associated with increased missed days of school or work, fear and mistrust in healthcare providers, and the development of chronic pain later in life [5,7]. It is important to understand that pain management in VOCs is guided by patient report of severity of pain [5,9]. While data suggesting that rapid administration of analgesia results in improved outcomes are mixed [10,11], best practice is to rapidly triage and administer analgesia to patients with SCD.

In 2014, the National Heart, Lung, and Blood Institute (NHLBI) published recommendations for the management of acute VOCs [12]. It is recommended the initial dose of analgesia be administered within 60 minutes of registration or within 30 minutes of triage of the patient [8,13,14]. A previously published study evaluating ED provider comfort and knowledge in managing acute sickle cell pain found that regardless of self-reported level of comfort in management, many providers were unaware of these NHLBI guidelines.

How to cite this article

Arnold T, Coffee R, Rosenberg L, et al. (September 25, 2022) A Quality Improvement Initiative to Decrease Time to Analgesia in Patients With Sickle Cell and Vaso-Occlusive Crisis: A Population With Disparities in Treatment. Cureus 14(9): e29569. DOI: 10.7759/cureus.29569
Intranasal fentanyl (INF) has previously been used as a rapid option for analgesia in many painful conditions. It is more potent than morphine with a high bioavailability, while the intranasal route leads to rapid delivery of the medication due to the highly vascularized nasal mucosa and direct connection to the central nervous system via the olfactory tissue. In 2018, Fenster et al. demonstrated non-inferiority of INF compared to intravenous (IV) morphine in patients requiring incision and drainage of abscesses.

Specific to SCD, studies have shown INF to provide rapid pain relief with higher provider and patient satisfaction, as well as a decrease in pain scores with INF, compared to placebo in patients with VOCs. Additionally, INF has been shown to decrease time to medication administration in a small study with a nurse-driven protocol and retrospectively. INF also provides an advantage in patients with SCD because obtaining IV access can be difficult due to scared veins secondary to their disease process and history of multiple IV sticks.

The primary aim of the quality improvement (QI) project was to have 75% of sickle cell patients with VOCs receive the first dose of either INF or IV analgesia within 60 minutes of registration using QI methodology, and in doing so, we also hoped to demonstrate decreased time to disposition.

Materials And Methods

This study was approved by the Indiana University Institutional Review Board as an exempt study. Riley Hospital for Children is a 379-bed tertiary care, free-standing pediatric hospital in Indianapolis, IN. The hospital is a level 1 pediatric trauma center with a 30-bed emergency department that sees over 52,000 patients per year. Providers in the emergency department include pediatric emergency medicine (PEM) physicians, general pediatricians, PEM fellows, residents (pediatrics, emergency medicine), and medical students. We utilized the SQUIRE (Standards for QUality Improvement Reporting Excellence) 2.0 guidelines to best design and execute this quality improvement study.

A multi-disciplinary team comprised of nurses, pharmacists, medical informaticists, pediatric hematology, and pediatric emergency medicine physicians determined barriers to meeting our goals using a key driver diagram. Data collection began in July 2018 prior to the first Plan-Do-Study-Act (PDSA) to determine the baseline time to analgesia and the route of administration of that medication prior to initiating the interventions. We used our electronic medical record (EMR) for data collection and included all sickle cell genotypes and patients under 18 years of age experiencing pain (International Classification of Diseases (ICD) 10 codes: D57.00, D57.01, D57.02, D57.211, D57.212, D57.219, D57.411, D57.419, D57.811, D57.819). ICD 10 codes for genotypes were confirmed by chart review. We excluded patients with acute chest, stroke, splenic sequestration, or fever.

The pre-intervention period for which data was collected was July 1, 2018, through December 31, 2018. The first PDSA cycle involving the use of a SCD order in the EMR began January 1, 2019, and ran through April 30, 2019. The second PDSA cycle in which we attended daily nursing meetings and instituted a rapid assessment protocol began May 1, 2019, and ran through the end of the data collection on June 30, 2020.
FIGURE 1: Flow diagram denoting the pre-intervention period through the second Plan-Do-Study-Act (PDSA) cycle

The initial intervention involved the formation of a "Sickle Cell Pain Management" order set within the EMR by this same multi-disciplinary team. This involved initial dose of medication, in addition to subsequent doses upon re-evaluation. It gave the providers a rapid method for ordering analgesia, providing multiple options, including intranasal fentanyl as the primary choice. It also allowed providers to order labs within the same order set.

The second PDSA cycle involved daily education and the initiation of a new process for rapid medication administration. The process began by the triage nurse using our ED all-call system to announce the room the patient with a VOC would be going to. We would then rapidly evaluate the patient as a team that included nursing, resident and/or fellow, and attending physician; patient care technicians and child life would be present for the initial assessment if in the ED. Traditionally the nurses would do their assessment and assign an Emergency Severity Index (ESI) triage level [19], followed by any learners before the attending physician would evaluate the patient. In the rapid evaluation, all involved persons would be notified by verbal notification and would go to the room immediately to perform an initial assessment. A brief history would be confirmed by all members of the team, a focused physical examination would be performed, and the first dose of analgesia would be ordered immediately in the patient room by the ordering physician (resident, fellow, or attending). This new process was discussed in daily nursing meetings for two weeks at the beginning of the second PDSA cycle. Physicians were encouraged to use both the order set and the new rapid evaluation process to quickly and rapidly order and deliver analgesia.

Each month we would evaluate all encounters for pain in patients with SCD and record the data points. We were evaluating each case for time to medication delivery, time to disposition, route of medication administration, age, sex, and SCD genotype. We then used standard t-tests in Microsoft Excel (Microsoft Corporation, Redmond, Washington) to determine statistical significance using individual group means. We used control charts to evaluate the data points for the percentage of patients meeting the goals and used run charts to evaluate the individual patients and time to medication administration.

**Results**

Over the two-year study period, we analyzed 251 encounters with a primary or secondary diagnosis of SCD and a chief complaint of pain. Fifty-five encounters were pre-intervention and 196 encounters were post-intervention. The mean age was 14 years old. Females were 49.5%, 50.5% were males, and all were African American. One-hundred fifty-two encounters involved patients with hemoglobin (Hb) SS disease, 64 encounters with Hb SC disease, 21 encounters with Hb S-Beta 0 thalassemia, and 14 encounters with Hb S-Beta + thalassemia.

The goal of 75% of patients receiving initial analgesia within 60 minutes from registration occurred in only one of the six (Jan-Jun) months leading up to the start of the initial PDSA cycle. During the intervention period, we achieved the goal in 13 of the 18 months (Figure 2).
During the pre-intervention data collection, the average time to medication administration was 62 minutes. This was decreased to 44 minutes through the entirety of the second PDSA cycle (p-value < 0.001) (Figure 3). The overall average time to disposition pre-intervention was 267 minutes and post-intervention was 227 minutes (p-value: 0.011). When we met the goal of administering the medication within 60 minutes from registration, there was an average time to disposition of 227 minutes, while, if the goal time was not met, the average time to disposition was 260 minutes (p-value: 0.025).

**Discussion**

The goal of the project was for 75% of patients with SCD seen for VOC to receive an initial dose of analgesia within 60 minutes of registration. In the 18 months since starting the PDSA cycles, we were able to attain the goal in thirteen of the eighteen months (72%), whereas in the six months of the initial data collection, pre-intervention, that was only achieved once (17%). Additionally, we decreased the time to medication administration and time to disposition from the pre-intervention group to the post-intervention group. This demonstrates that the process of rapid team evaluation is effective for timely patient assessment and medication administration, regardless of which medication is used.

Previously, INF had been shown to decrease time to medication administration in a small study with a nurse-driven protocol [17]; however, this can be difficult to implement broadly, as many facilities, including
our own, will not approve nurse-driven protocols for delivery of opiate analgesia. While we did see a shorter
time to medication administration with INF versus IV medication in the study, we did not see a difference in
time to disposition. We did, however, see a difference in time to disposition when patients received their
initial analgesia within 60 minutes, which suggests that the process of rapid evaluation and medication
administration is more important than the route of medication delivery. Kelly et al. retrospectively showed a
similar decrease in time to analgesia [13]; however, it is unclear if any QI methodology was used in their
processes.

Pain management in VOC, as recommended by the NHLBI, as well as the American Society of Hematology
and the American Academy of Pain Medicine, should be guided by patient report of severity [8,9]. However, a
study has shown that healthcare providers are more likely to perceive patients with SCD as drug-seeking or
opioid-dependent, which results in inadequate treatment and more suffering [20]. While data suggesting
that rapid administration of analgesia results in improved outcomes are mixed, the best practice is to rapidly
triage and administer analgesia to patients with SCD. It is crucial to treat self-reported pain in a timely
manner to avoid fear and mistrust in healthcare providers and the development of chronic pain later in life.
We show here that with appropriate rapid evaluation and medication administration, regardless of the
medication, we can more quickly and efficiently treat and disposition a population that previously has had
disparities in management.

Study limitations include the lack of data related to time from triage. In the NHLBI guidelines, the
recommendation is for sixty minutes from registration or thirty minutes from triage. However, using our
EMR, it is difficult to track the triage time as there is no definitive marker for this. Therefore, in the analysis,
we decided to use the time from registration as we knew this would be a more reliable method when
reviewing our patient encounters. One of the other difficulties we encountered was with nursing turnover.
National ED nursing turnover is 14% [21] and during 2019 we had 35% nursing turnover. Despite this
turnover rate, we were successful with the initiative, suggesting this is a viable intervention to improve
analgesia time for patients with SCD. At our hospital, we do use similar alerts for other painful processes,
such as long bone fractures, so it allowed for adaptability for our patients with SCD, which may have aided in
our success despite higher turnover. Additionally, this was a single-center study and further studies would
need to be done to see if this is generalizable on a larger scale. Any patient with a history of SCD underwent
rapid assessment team evaluation regardless of age, pain severity, time of day, or other confounding factors.

Conclusions
Using QI methodology, we were able to increase the percent of patients meeting the NHLBI
recommendations for first dose of analgesia within 60 minutes of triage for patients presenting with VOC in
a majority of the months during the post-intervention period. This represents a statistically significant
increase from the pre-intervention period. The greatest improvement was seen following the initiation of
our rapid evaluation process. Furthermore, we showed improved time to analgesia in patients with VOCs
and significantly decreased time to disposition regardless of route of medication administration. This was
unique to this study as other similar studies showed their results exclusively with the intranasal route of
administration and unrelated to time to disposition. Other EDs may be able to utilize similar QI
methodology to improve the care of patients with VOC and meet the NHLBI recommendations.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Indiana University
Institutional Review Board issued approval Exempt. This study was approved by the Indiana University
Institutional Review Board as an exempt study. Animal subjects: All authors have confirmed that this study
did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform
disclosure form, all authors declare the following: Payment/services info: All authors have declared that no
financial support was received from any organization for the submitted work. Financial relationships: All
authors have declared that they have no financial relationships at present or within the previous three years
with any organizations that might have an interest in the submitted work. Other relationships: All authors
have declared that there are no other relationships or activities that could appear to have influenced the
submitted work.

References
1. Hassell KL: Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010, 38:S512-21.
   10.1016/j.amepre.2009.12.022
2. Sickle Cell Disease Guideline Panel: Sickle cell disease: screening, diagnosis, management and counseling
   in newborns and infants. Clinical Practice Guideline No. 6 AHCPR Pub. No. 95 0562. Agency for Health Care
   Policy and Research, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD;
   1995.
3. Bainbridge R, Higgs DR, Maude GH, Serjeant GR: Clinical presentation of homozygous sickle cell disease. J
   Pediatr. 1985, 106:881-5. 10.1016/s0022-3476(85)80250-4
4. Woods K, Karrison T, Koshy M, Patel A, Friedmann P, Cassel C: Hospital utilization patterns and costs for
   hospitalization as a function of patient race and diagnosis. JAMA. 1989, 261:2164-9.
   10.1001/jama.1989.03470080048032
5. Woods K, Karrison T, Koshy M, Patel A, Friedmann P, Cassel C: Hospitalization as a function of patient race and
   diagnosis. JAMA. 1989, 261:2164-9.
   10.1001/jama.1989.03470080048032
adult sickle cell patients in Illinois. Public Health Rep. 1997, 112:44-51.

5. Haywood C Jr, Tanabe P, Naik R, Beach MC, Lanzkron S: The impact of race and disease on sickle cell patient wait times in the emergency department. Am J Emerg Med. 2015, 31:651-6. 10.1016/j.ajem.2012.11.005

6. Institute of Medicine (U.S.): Relieving Pain in America: Blueprint for Transforming Prevention, Care, Education, and Research. National Academies Press, Washington, D.C.; 2011. 10.17226/13172

7. Rizio AA, Bhor M, Lin X, et al.: The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease. Qual Life Res. 2020, 29:1533-47. 10.1007/s11136-019-02412-5

8. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. (2014). Accessed: July 27, 2022: https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease.

9. Ballas SK: The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin. 1995, 19:323-33. 10.3109/03630269509005824

10. Benjamin LJ, Swinson GI, Nagel RL: Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000, 95:1130-6. 10.1182/blood.V95.4.1130.003k03a_1130_1136

11. Fein DM, Avner JR, Scharbach K, Manwani D, Khine H: Intranasal fentanyl for initial treatment of vaso-occlusive crisis in sickle cell disease. Pediatr Blood Cancer. 2017, 64: e26332. 10.1002/pbc.26332

12. Glassberg JA: Improving emergency department-based care of sickle cell pain. Hematology Am Soc Hematol Educ Program. 2017, 2017:412-7. 10.1182/asheducation-2017.1.412

13. Kelly GS, Stewart RW, Strouse JJ, Anders JF: Intranasal fentanyl improves time to analgesic delivery in sickle cell pain crises. Am J Emerg Med. 2018, 36:1305-7. 10.1016/j.ajem.2017.11.015

14. Simon E, Long B, Koyman A: Emergency medicine management of sickle cell disease complications: an evidence-based update. J Emerg Med. 2016, 51:570-81. 10.1016/j.jemermed.2016.05.042

15. Martin OY, Thompson SM, Carroll AE, Jacob SA: Emergency department provider survey regarding acute sickle cell pain management. J Pediatr Hematol Oncol. 2020, 42:575-80. 10.1097/MPH.0000000000001843

16. Fenster DB, Dayan PS, Babineau J, Aponte-Patel L, Tszte DS: Randomized trial of intranasal fentanyl versus intravenous morphine for abscess incision and drainage. Pediatr Emerg Care. 2018, 34:607-12. 10.1097/PEC.0000000000000810

17. Akinsola B, Haghnon R, Zmitrovich A, et al.: Impact of intranasal fentanyl in nurse initiated protocols for sickle cell vaso-occlusive pain episodes in a pediatric emergency department. Am J Hematol. 2018, 93:e205-7. 10.1002/ajh.25144

18. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D: SQUARE 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf. 2016, 25:986-92. 10.1136/bmjqs-2015-004411

19. Christ M, Grossmann F, Winter D, Bingisser R, Platz E: Modern triage in the emergency department. Dtsch Arztebl Int. 2010, 107:892-8. 10.3238/arztebl.2010.0892

20. Power-Hays A, McGann PT: When actions speak louder than words - racism and sickle cell disease. N Engl J Med. 2020, 383:1902-3. 10.1056/NEJMcp2002125

21. McDermid F, Mannix J, Peters K: Factors contributing to high turnover rates of emergency nurses: a review of the literature. Aust Crit Care. 2020, 33:590-6. 10.1016/j.aucc.2019.09.002